According to a recent LinkedIn post from Glooko, company-affiliated physician Paul Chidester, M.D., FACP, is set to present new clinical data at the 2026 American Association of Clinical Endocrinology Annual Meeting in Las Vegas. The presentation is described as focusing on the EndoTool Glucose Management System, originally developed by Monarch Medical Technologies, and its role in inpatient diabetes and glycemic care.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that the data will cover deployment of EndoTool across a 19-hospital health system in North Carolina, in collaboration with Advocate Health Wake Forest Baptist Hospital’s Joe Aloi, M.D., FACE. For investors, the emphasis on multi-hospital, systemwide use suggests potential for broader adoption of Glooko-related or integrated technologies in inpatient settings.
If the data demonstrate meaningful improvements in glycemic safety and clinical outcomes, this could strengthen Glooko’s positioning within hospital-focused diabetes management solutions relative to digital-health competitors. Increased clinical validation and visibility at a major endocrine conference may also support future commercial discussions with large health systems and payers, with possible long-term implications for revenue growth and partnership pipelines.